93 related articles for article (PubMed ID: 22771509)
21. Association of serum bactericidal antibody and opsonic antibody levels after Neisseria meningitidis serogroup C conjugate vaccine in Brazilian children and adolescents infected or not infected with HIV.
Pereira-Manfro WF; Alvino RM; Cruz AC; Silva GP; Castro RB; Ferreira B; Barreto DM; Frota AC; Hofer CB; Milagres LG
Vaccine; 2016 Dec; 34(50):6116-6119. PubMed ID: 27847176
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
[TBL] [Abstract][Full Text] [Related]
23. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
24. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
Balmer P; Borrow R
Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
[TBL] [Abstract][Full Text] [Related]
26. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
Bröker M; Veitch K
Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.
Frota AC; Milagres LG; Harrison LH; Ferreira B; Menna Barreto D; Pereira GS; Cruz AC; Pereira-Manfro W; de Oliveira RH; Abreu TF; Hofer CB
Pediatr Infect Dis J; 2015 May; 34(5):e113-8. PubMed ID: 25876102
[TBL] [Abstract][Full Text] [Related]
29. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
[TBL] [Abstract][Full Text] [Related]
31. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
[TBL] [Abstract][Full Text] [Related]
32. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
33. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.
de Kleijn ED; de Groot R; Lafeber AB; Labadie J; van Limpt CJ; Visser J; Berbers GA; van Alphen L; Rümke HC
J Infect Dis; 2001 Jul; 184(1):98-102. PubMed ID: 11398116
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
35. Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
Frota ACC; Ferreira B; Harrison LH; Pereira GS; Pereira-Manfro W; Machado ES; de Oliveira RH; Abreu TF; Milagres LG; Hofer CB
Vaccine; 2017 Dec; 35(50):7042-7048. PubMed ID: 29100708
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger.
Chippaux JP; Garba A; Ethevenaux C; Campagne G; de Chabalier F; Djibo S; Nicolas P; Ali H; Charrondière M; Ryall R; Bybel M; Schuchat A
Vaccine; 2004 Sep; 22(25-26):3303-11. PubMed ID: 15308353
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
38. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
39. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
40. Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals.
Milagres L; Silva G; Pereira-Manfro W; Frota AC; Hofer C; Ferreira B; Barreto D; Figueredo M; Coelho B; Villela L; Petrovas C; Koup R
Front Immunol; 2018; 9():2500. PubMed ID: 30420858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
